Journal
THERAPEUTIC DELIVERY
Volume 3, Issue 8, Pages 961-979Publisher
FUTURE SCI LTD
DOI: 10.4155/TDE.12.75
Keywords
-
Categories
Funding
- NIH [R01-CA129528]
- AFPE Pre-Doctoral Fellowship
Ask authors/readers for more resources
The current status of peptides that target the mitochondria in the context of cancer is the focus of this review. Chemotherapy and radiotherapy used to kill tumor cells are principally mediated by the process of apoptosis that is governed by the mitochondria. The failure of anticancer therapy often resides at the level of the mitochondria. Therefore, the mitochondrion is a key pharmacological target in cancer due to many of the differences that arise between malignant and healthy cells at the level of this ubiquitous organelle. Additionally, targeting the characteristics of malignant mitochondria often rely on disruption of protein-protein interactions that are not generally amenable to small molecules. We discuss anticancer peptides that intersect with pathological changes in the mitochondrion.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available